Australia: TGA cancels Prexige registration over liver risks

08/12/2007 | MarketWatch

Australia's Therapeutic Goods Administration moved Saturday to cancel the registration of Novartis AG's pain drug Prexige after reports of liver damage risks surfaced. Prexige, a Cox-2 inhibitor similar to Vioxx, reportedly caused liver-related adverse reactions in the eight cases received by the TGA.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Marlborough, MA
Test Technician
Marlborough, MA